Icon

LYRICA CR - (82.5,165 mg; Tablet, Extended Release)

Pregabalin Pfizer
82.5,165 mg; Tablet, Extended Release
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
More Than 5
More Than 5
Used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection
Yes
*** ****** ***** * *********** ******** ******* * *********** **** *** *** **** ******** **** *** ******** ’***, ’*** ** ’*** *******
LYRICA CR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** ****** *** ********* **** *** *** ********* *** ********* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ ********* *** ********* *** ********* ******** ******** ** *** **, ****
  1. *** *, **** : *** ****** ******** ****** ***** **'* **** ** ****** **** ******* ******* (*** *,****) *** ******* (*** *,****)
  2. *** **, **** : *** ****** ******** ****** ***** **'* **** ** ****** **** ****** ******** (*** *,****)
  3. *** *, **** : *** ****** ***** * *********** ******** ******* * *********** **** *** *** **** ******** **** *** ******** ’***, ’*** ** ’*** *******

LYRICA CR - (330mg; Tablet ER)

Pregabalin Pfizer
330mg; Tablet ER
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
More Than 5
More Than 5
Used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection
Yes
*** ****** ***** * *********** ******** ******* * *********** **** *** *** **** ******** **** *** ******** ’***, ’*** ** ’*** *******
LYRICA CR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** ****** *** ********* **** *** *** ********* *** ********* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** ****** *** \ ********* *** ********* *** ********* ******** ******** ** *** **, ****
  1. *** **, **** : *** ****** ******** ****** ***** **'* **** ** ****** **** ******* ******* (*** *,****) *** ******* (*** *,****)
  2. *** **, **** : *** ****** ******** ****** ***** **'* **** ** ****** **** ****** ******** (*** *,****)
  3. *** *, **** : *** ****** ***** * *********** ******** ******* * *********** **** *** *** **** ******** **** *** ******** ’***, ’*** ** ’*** *******

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.